Luminex Corporation (LMNX) EPS Estimated At $0.11

January 22, 2018 - By Richard Conner

 Luminex Corporation (LMNX) EPS Estimated At $0.11

Analysts expect Luminex Corporation (NASDAQ:LMNX) to report $0.11 EPS on February, 5.They anticipate $0.19 EPS change or 237.50 % from last quarter’s $-0.08 EPS. LMNX’s profit would be $4.85 million giving it 46.73 P/E if the $0.11 EPS is correct. After having $0.19 EPS previously, Luminex Corporation’s analysts see -42.11 % EPS growth. The stock decreased 0.39% or $0.08 during the last trading session, reaching $20.56. About 174,639 shares traded. Luminex Corporation (NASDAQ:LMNX) has risen 6.31% since January 22, 2017 and is uptrending. It has underperformed by 10.39% the S&P500.

Luminex Corporation (NASDAQ:LMNX) Ratings Coverage

Among 8 analysts covering Luminex Corp (NASDAQ:LMNX), 3 have Buy rating, 1 Sell and 4 Hold. Therefore 38% are positive. Luminex Corp had 15 analyst reports since August 4, 2015 according to SRatingsIntel. The firm has “Hold” rating given on Sunday, September 17 by Piper Jaffray. The company was maintained on Friday, June 9 by Jefferies. As per Tuesday, August 4, the company rating was upgraded by Wedbush. The stock of Luminex Corporation (NASDAQ:LMNX) earned “Hold” rating by Jefferies on Friday, October 20. Jefferies maintained it with “Hold” rating and $19 target in Wednesday, August 5 report. The stock of Luminex Corporation (NASDAQ:LMNX) earned “Mkt Outperform” rating by Avondale on Wednesday, October 12. The stock of Luminex Corporation (NASDAQ:LMNX) earned “Hold” rating by Piper Jaffray on Monday, October 23. The rating was maintained by Jefferies on Wednesday, September 13 with “Hold”. JP Morgan upgraded the shares of LMNX in report on Thursday, August 18 to “Neutral” rating.

Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the diagnostics, pharmaceutical, and life sciences industries worldwide. The company has market cap of $905.76 million. The company??s products include Luminex LX 100/200 that integrates fluidics, optics, and digital signal processing; FLEXMAP 3D system for use as a general laboratory instrument; MAGPIX system, a multiplexing analyzer for qualitative and quantitative analysis of proteins and nucleic acids; Verigene system, an automated multiplex-capable system; and ARIES system, a sample to answer real-time PCR platform. It has a 31.1 P/E ratio. It also offers MicroPlex, MagPlex, xTAG, SeroMAP, and calibration and control microspheres; ARIES cassettes that are self-contained assay consumables; xPONENT, a software suite to simplify laboratory workflow and enhance productivity; SYNCT data management software solutions; respiratory viral family of products to identify the causative agent for respiratory infections; and gastrointestinal pathogen panel assays to identify the pathogens causing infectious gastroenteritis.

More recent Luminex Corporation (NASDAQ:LMNX) news were published by: Prnewswire.com which released: “Luminex Corporation Declares Fourth Quarter Cash Dividend” on November 01, 2017. Also Seekingalpha.com published the news titled: “Can Luminex Light The Way?” on November 14, 2017. Prnewswire.com‘s news article titled: “Luminex Corporation Receives FDA Clearance for ARIES Group A Strep Assay” with publication date: October 31, 2017 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.



Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: